Bispecific antibodies for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at using bispecific antibodies (a type of immune therapy) to help people with multiple myeloma who have relapsed or stopped responding to other treatments. It aims to better understand why some patients may not respond or relapse after this targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma
- You are being considered for a bispecific antibody or other myeloma treatment (like CAR-T)
- You are able to have a bone marrow sample taken
- You are not pregnant
- You are at least 18 years old and legally able to consent
- You can understand and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a bispecific antibody (BCMA/CD3) given as a short-term treatment before CAR-T cell therapy in people with multiple myeloma that has come back or stopped responding to multiple treatments. The goal is to see if this approach can help control the disease while CAR-T cells are being prepared.
This trial tests a combination of two drugs—belantamab mafodotin and mezigdomide—to treat multiple myeloma that has come back after previous treatments. It's designed for patients whose myeloma has not responded well to standard therapies.
This trial tests a new treatment using your own immune cells, modified to find and attack a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has come back or not responded to at least three prior treatments.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a new type of immune cell therapy using donated umbilical cord blood cells that are modified to target two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or is not responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.